Use of suboptimal control arms in randomized clinical trials of investigational cancer drugs in China, 2016 –2021: An observational study
ConclusionsIn this study, over one-eighth of randomized trials of cancer drugs registered to apply for regulatory approval in China used a suboptimal comparator. Our results highlight the necessity to refine the design of randomized trials to generate optimal clinical evidence for new cancer therapies.
Source: PLoS Medicine - Category: Internal Medicine Authors: Yichen Zhang Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | China Health | Clinical Trials | Internal Medicine | Investigational New Drugs | Medical Ethics | New Drug Applications | Statistics | Study